Artelo says preclinical osteoarthritis study shows ART26.12 matches naproxen pain relief with less gastric damage

Artelo Biosciences Inc

Artelo Biosciences Inc

ARTL

0.00
  • Artelo Biosciences reported nonclinical osteoarthritis data showing oral ART26.12 reduced pain behaviors over 4 weeks with efficacy comparable to naproxen.
  • Preclinical results showed significantly less stomach tissue damage versus naproxen, signaling a potentially improved gastrointestinal safety profile for chronic use.
  • Artelo plans a multiple ascending repeat-dose clinical study in healthy volunteers, with enrollment expected to start in Q4.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607160848PRIMZONEFULLFEED9763234) on July 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.